TY - JOUR
T1 - Engineering the supernatural
T2 - monoclonal antibodies for challenging infectious diseases
AU - Grace, Patricia S.
AU - Gunn, Bronwyn M.
AU - Lu, Lenette L.
N1 - Funding Information:
This work is supported by Harvard School of Public Health Yerby Research Fellowship (to P.S.G), NIH/ NCI U54CA260581 (to B.M.G), NIH/NIAID U19AI142777 (to B.M.G), NIH/NIAID U01AI151378 (to B.M.G), and NIH/NIAD 5R01AI158858-02 (to L.L.L.). We are forever grateful to Todd J. Suscovich for his influence on our scientific development at the intersection of antibodies and infectious disease.
Publisher Copyright:
© 2022
PY - 2022/12
Y1 - 2022/12
N2 - The COVID-19 pandemic demonstrated that monoclonal antibodies can be deployed faster than antimicrobials and vaccines. However, the majority of mAbs treat cancer and autoimmune diseases, whereas a minority treat infection. This is in part because targeting a single antigen by the antibody Fab domain is insufficient to stop the dynamic microbial life cycle. Thus, finding the ‘right’ antigens remains the focus of intense investigations. Equally important is the antibody-Fc domain that has the capacity to induce immune responses that enhance neutralization, and limit pathology and transmission. While Fc-effector functions have been less deeply studied, conceptual and technical advances reveal previously underappreciated antibody potential to combat diseases from microbes difficult to address with current diagnostics, therapeutics, and vaccines, including S. aureus, P. aeruginosa, P. falciparum, and M. tuberculosis. What is learned about engineering antibodies for these challenging organisms will enhance our approach to new and emerging infectious diseases.
AB - The COVID-19 pandemic demonstrated that monoclonal antibodies can be deployed faster than antimicrobials and vaccines. However, the majority of mAbs treat cancer and autoimmune diseases, whereas a minority treat infection. This is in part because targeting a single antigen by the antibody Fab domain is insufficient to stop the dynamic microbial life cycle. Thus, finding the ‘right’ antigens remains the focus of intense investigations. Equally important is the antibody-Fc domain that has the capacity to induce immune responses that enhance neutralization, and limit pathology and transmission. While Fc-effector functions have been less deeply studied, conceptual and technical advances reveal previously underappreciated antibody potential to combat diseases from microbes difficult to address with current diagnostics, therapeutics, and vaccines, including S. aureus, P. aeruginosa, P. falciparum, and M. tuberculosis. What is learned about engineering antibodies for these challenging organisms will enhance our approach to new and emerging infectious diseases.
UR - http://www.scopus.com/inward/record.url?scp=85139591498&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139591498&partnerID=8YFLogxK
U2 - 10.1016/j.copbio.2022.102818
DO - 10.1016/j.copbio.2022.102818
M3 - Review article
C2 - 36242952
AN - SCOPUS:85139591498
SN - 0958-1669
VL - 78
JO - Current Opinion in Biotechnology
JF - Current Opinion in Biotechnology
M1 - 102818
ER -